BioE Seminar: “Engineering of MRI to address evolving needs in cardiovascular research and clinical practice”

Seminar | February 1 | 12-1 p.m. | 290 Hearst Memorial Mining Building

 Moriel Vandsburger, UC Berkeley

 Bioengineering (BioE)

Spring 2017 Seminar Series

Wednesday, February 1
12noon - 1:00pm
290 Hearst Mining Building

“Engineering of MRI to address evolving needs in cardiovascular research and clinical practice”

Moriel Vandsburger
Assistant Professor of Bioengineering
UC Berkeley

Extensive use of in vivo and cellular imaging with fluorescent and luminescent reporter genes and dyes has been instrumental to fundamental research into molecular and cellular mechanisms of disease. However, the inability to use such tools in clinical settings forces corresponding longitudinal monitoring of cellular and molecular events in humans to be performed on excised tissue samples. The reliance upon repeated and painful tissue biopsy remains an obstacle to clinical application of fundamental discoveries that can lead to better care. Existing imaging technologies generally offer a trade-off between diagnosis of changes in organ structure/function and molecular imaging of a single biological target. In this seminar I will discuss the design and application of non-invasive in vivo molecular MRI as a means to quantify and integrate biological phenomena and diagnostic measures across multiple physical scales (i.e. from the level of gene expression up to whole organ characterization) and biological platforms (i.e. from pre-clinical models to clinical populations). This talk will focus on the cardiac specific design and application of chemical exchange saturation transfer (CEST) imaging to selectively encode molecular contrast from reporter genes, contrast agents, and endogenous macromolecules into the steady state magnetization of the heart. Similar to fluorescence microscopy, the contrast from each target is selectively ‘turned on’ without altering the native MR image integrity to enable quantitative imaging of multiple molecular targets with automatic registration to anatomical origin and functional measurements. Specific examples will include models of gene and cell therapy and diagnostic imaging in high risk patient populations as platforms for early technological development. Future directions of this work will be discussed.